Prothena offers deeply discounted, partner-funded biotech optionality where two Phase 3 shots on goal could transform today’s cash-rich clinical platform into a high-margin royalty engine.
Overview
Prothena is a late-stage biotech focused on immunotherapies for protein-misfolding diseases, including Parkinson’s, ATTR-CM, and Alzheimer’s. It has no recurring product revenue today, but its out-licensed pipeline gives it exposure to Roche, Novo Nordisk, and BMS-funded global trials, with potential milestones and high-margin royalties. Key assets include Phase 3 prasinezumab and coramitug, Phase 2 BMS-986446, and next-generation CYTOPE programs. The investment case rests on large unmet markets, strong partners, differentiated antibody engineering, and asymmetric upside if late-stage trials succeed.